OncoMatch/Clinical Trials/NCT07783477
A Study of Armored CAR T Cells in People With Cancer
Is NCT07783477 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies DLL3-SAVVYZ-IL18 CAR T cell for neuroendocrine cancer.
Treatment: DLL3-SAVVYZ-IL18 CAR T cell — The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 expression (expression detected by IHC)
DLL3 expression detected by IHC using archival tumor tissue or tissue obtained from a biopsy performed as part of standard clinical care
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — limited or extensive stage disease
one line of approved systemic therapy for limited or extensive stage disease and has progressed or is no longer deriving benefit or standard treatment is no longer tolerable or declines further standard treatment
Must have received: platinum-based chemotherapy
Prior treatment should include an approved platinum-based regimen with/without ICI therapy if applicable to their disease
Lab requirements
Blood counts
Hgb > 9 g/dL, platelets > 75 x10^3/ul
Kidney function
serum creatinine < 2.0 mg/dL (> 18 years) or ≤ 2.5 x institutional upper limit of normal (ULN) for age. If serum creatinine is outside the normal range, then CrCl > 40 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.73m2) > 40% of predicted normal for age.
Liver function
Serum total bilirubin ≤1.5 mg/dL (unless Gilbert's syndrome), albumin > 3 g/dL. ALT and AST < 5 times the upper limit of normal unless thought to be disease-related.
Cardiac function
LVEF ≥ 50% by resting echocardiogram
Adequate organ function is required, defined as follows: Hematologic: Hgb > 9 g/dL, platelets > 75 x10^3/ul; Hepatic: Serum total bilirubin ≤1.5 mg/dL (unless Gilbert's syndrome), albumin > 3 g/dL. Hepatic: ALT and AST < 5 times the upper limit of normal unless thought to be disease-related. Renal: serum creatinine < 2.0 mg/dL (> 18 years) or ≤ 2.5 x institutional upper limit of normal (ULN) for age. If serum creatinine is outside the normal range, then CrCl > 40 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.73m2) > 40% of predicted normal for age. Cardiac: LVEF ≥ 50% by resting echocardiogram. Pulmonary: Adequate pulmonary function as assessed by ≥ 92% oxygen saturation on room air by pulse oximetry
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07783477 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and platinum-based chemotherapy.
Does this trial require DLL3?
Yes, DLL3 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify